[Treatment of obstetrical blood coagulation defects].
D062365:Aminobenzoates / Q000627:therapeutic use; D000614:Aminocaproates / Q000627:therapeutic use; D000818:Animals; D007611:Aprotinin / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000503:physiopathology; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D017713:Platelet Transfusion; D006473:Postpartum Hemorrhage / Q000188:drug therapy; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy* / Q000503:physiopathology; D011480:Protease Inhibitors; D011817:Rabbits; D051381:Rats; D013300:Streptokinase / Q000627:therapeutic use
D062365:Aminobenzoates; D000614:Aminocaproates; D005343:Fibrinolytic Agents; D011480:Protease Inhibitors; D005340:Fibrinogen; D006493:Heparin; D007611:Aprotinin; D013300:Streptokinase
Grundlagen zur Behandlung von Blutungsstörungen in der Geburtshilfe.